CONCOURSE FINANCIAL GROUP SECURITIES, INC. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.

Quarter-by-quarter ownership
CONCOURSE FINANCIAL GROUP SECURITIES, INC. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$9,168
-18.3%
202
+1.0%
0.00%0.0%
Q2 2023$11,228
+24.1%
2000.0%0.00%0.0%
Q1 2023$9,046
+11.3%
2000.0%0.00%0.0%
Q4 2022$8,1302000.00%
Q3 2022$0
-100.0%
0
-100.0%
0.00%
-100.0%
Q2 2022$12,000
-7.7%
2000.0%0.00%0.0%
Q1 2022$13,000
-59.4%
200
-52.9%
0.00%
-50.0%
Q4 2021$32,000
-42.9%
425
-15.2%
0.00%
-33.3%
Q3 2021$56,000
-35.6%
501
-7.2%
0.00%
-40.0%
Q2 2021$87,000
+50.0%
540
+13.0%
0.01%
+25.0%
Q1 2021$58,000
+52.6%
478
+94.3%
0.00%
+33.3%
Q4 2020$38,000
+153.3%
246
+34.4%
0.00%
+200.0%
Q3 2020$15,000
-16.7%
183
-23.8%
0.00%
-50.0%
Q2 2020$18,000
+350.0%
240
+140.0%
0.00%
Q1 2020$4,000
-33.3%
1000.0%0.00%
-100.0%
Q4 2019$6,0001000.00%
Q3 2019$000.00%
Q2 2019$000.00%
Q1 2019$000.00%
Q4 2018$000.00%
Q3 2018$000.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders